It has been about a month since the last earnings report for Axsome Therapeutics (AXSM Quick QuoteAXSM - Free Report) . Shares have lost about 1.8% in that time frame, underperforming the S&P 500.

Will the recent negative trend continue leading up to its next earnings release, or is Axsome due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

How Have Estimates Been Moving Since Then?

It turns out, fresh estimates flatlined during the past month.

VGM Scores

Currently, Axsome has an average Growth Score of C, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.

Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Axsome has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry Player

Axsome is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Moderna (MRNA Quick QuoteMRNA - Free Report) , a stock from the same industry, has gained 13.8%. The company reported its results for the quarter ended March 2025 more than a month ago.

Moderna reported revenues of $108 million in the last reported quarter, representing a year-over-year change of -35.3%. EPS of -$2.52 for the same period compares with -$3.07 a year ago.

Moderna is expected to post a loss of $2.97 per share for the current quarter, representing a year-over-year change of +10.8%. Over the last 30 days, the Zacks Consensus Estimate has changed -3.9%.

Moderna has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D.